HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • LipoADC™ Platform – K1
    • TRAFsome™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文
HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • LipoADC™ Platform – K1
    • TRAFsome™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (12)
  • Publications (14)
  • References (21)
  • Uncategorized (6)

Recent Posts

Post placeholder image
September 18, 2024

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative
Post placeholder image
September 16, 2024

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

by PJWCreative
Post placeholder image
September 4, 2024

HighField Biopharmaceuticals Company Profile – 2024

by PJWCreative
Post placeholder image
September 3, 2024

HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers

by PJWCreative
Post placeholder image
August 8, 2024

ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

by PJWCreative
Post placeholder image
June 24, 2024

HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss

by PJWCreative

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
November 2, 2018 in Publications

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
July 1, 2018 in Publications

Molecular Cancer Therapeutics: Selective Targeting and Eradication of LGR5+ Cancer Stem Cells Using RSPO-Conjugated Doxorubicin Liposomes

PJWCreative 0 Like Post Comments Off on Molecular Cancer Therapeutics: Selective Targeting and Eradication of LGR5+ Cancer Stem Cells Using RSPO-Conjugated Doxorubicin Liposomes
Read More
Post placeholder image
September 5, 2008 in Publications

Preclinical Manufacture of an Anti-HER2 scFv-PEG-DSPE, Liposome-Inserting Conjugate. 1. Gram-Scale Production and Purification

PJWCreative 0 Like Post Comments Off on Preclinical Manufacture of an Anti-HER2 scFv-PEG-DSPE, Liposome-Inserting Conjugate. 1. Gram-Scale Production and Purification
Read More
Post placeholder image
June 3, 1980 in Publications

Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)

PJWCreative 0 Like Post 0 Comment
Read More
Prev12Next

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

© 2024 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc

en_US English
en_US English
zh_CN 简体中文